Roth Capital resumed coverage of CapsoVision (CV) with a Buy rating and $7 price target The firm says the two label expansions in December 2024, to include pediatrics as young as two and remote ingestions, will help to accelerate adoption of the company’s “best-in-class” device. It sees clearance of Gen 1 CapsoCam Colon as well as submissions for CapsoVision’s small bowel artificial intelligence module as additional catalysts for the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CV: